NCT03987295View on ClinicalTrials.gov

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 27, 2019

Primary Completion Date

June 5, 2024

Study Completion Date

June 5, 2024

Conditions
Frontotemporal Dementia
Interventions
DRUG

AL001

60 mg/kg of AL001 every 4 weeks

Trial Locations (12)

19104

University of Pennsylvania, Philadelphia

25123

University of Brescia, Brescia

55905

Mayo Clinic, Rochester

78229

The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases UT Health San Antonio, San Antonio

81675

Technical University of Munich, München

89081

University of Ulm, Ulm

94158

UCSF, San Francisco

N6A 4V2

Lawson Health Research Institute, St. Joseph's, London

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

1081GN

Brain Research Center - PPDS, Amsterdam

3015 GD

Erasmus University Medical Center, Rotterdam

WC1N 3BG

University College London, London

Sponsors

Lead Sponsor

Alector Inc.

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Alector Inc.

INDUSTRY

NCT03987295 - A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) | Biotech Hunter | Biotech Hunter